News Releases

ROCKVILLE, Md. and SHANGHAI, China , Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB ) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies

FDA granted Breakthrough Therapy Designation for felzartamab in PMN upon positive clinical data from M-PLACE, a Phase 2 study led by I-Mab partner HI-Bio I-Mab has full development and commercialization rights of felzartamab in Greater China for all indications, with Phase 3 multiple myeloma data

ROCKVILLE, MD , U.S. and SHANGHAI, China , Nov. 1, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB ) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel

ROCKVILLE, Md. and SHANGHAI, China , Oct. 16, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB ) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel

-        Among 14 efficacy-evaluable patients in the ongoing Phase 1 study, one achieved a complete response, one had partial response and two unconfirmed partial responses; maximum tolerated dose not yet reached -        Patent rights secured for TJ-L14B/ABL503 in Eurasia until 2039 ROCKVILLE,

ROCKVILLE, Md. and SHANGHAI , Sept. 5, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB ) (the "Company"), is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies

Significant progress made year-to-date on key clinical assets: ‐         Uliledlimab  (CD73 antibody): Encouraging early results were presented at ASCO 2023 ‐         Givastomig  (Claudin 18.2 x 4-1BB bispecific antibody): Topline Phase 1 data with promising early efficacy signals, including

ROCKVILLE, Md. and SHANGHAI , Aug. 8, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced that it will report business and corporate

GAITHERSBURG, Md. and SHANGHAI , July 5, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering  immunotherapies, today announced the publication of a manuscript entitled

GAITHERSBURG, Md. and SHANGHAI , June 22, 2023 /PRNewswire/ -- I-Mab (" I-Mab " or the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced the appointment of Mr.